ATE72629T1 - Cyclosporin enthaltende pharmazeutische zubereitung. - Google Patents

Cyclosporin enthaltende pharmazeutische zubereitung.

Info

Publication number
ATE72629T1
ATE72629T1 AT88305138T AT88305138T ATE72629T1 AT E72629 T1 ATE72629 T1 AT E72629T1 AT 88305138 T AT88305138 T AT 88305138T AT 88305138 T AT88305138 T AT 88305138T AT E72629 T1 ATE72629 T1 AT E72629T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
preparation containing
containing cyclosporin
cyclosporin
cyclosporins
Prior art date
Application number
AT88305138T
Other languages
German (de)
English (en)
Inventor
Kozo Kurihara
Masaru Murano
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE72629T1 publication Critical patent/ATE72629T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT88305138T 1987-06-04 1988-06-06 Cyclosporin enthaltende pharmazeutische zubereitung. ATE72629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14070387 1987-06-04
EP88305138A EP0294239B1 (en) 1987-06-04 1988-06-06 Cyclosporin-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE72629T1 true ATE72629T1 (de) 1992-03-15

Family

ID=15274767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88305138T ATE72629T1 (de) 1987-06-04 1988-06-06 Cyclosporin enthaltende pharmazeutische zubereitung.

Country Status (10)

Country Link
US (1) US5051402A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0294239B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2577049B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE72629T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU607506B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1325973C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3868438D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2033429T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3004199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK28097A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH07111785B2 (ja) 1990-01-19 1995-11-29 富士通株式会社 光ディスク
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
FR2670629B1 (fr) * 1990-12-17 1995-03-10 Moving Magnet Tech Actionneur electromagnetique monophase rotatif.
DE69222150T2 (de) * 1991-01-25 1998-01-15 Fujisawa Pharmaceutical Co Prozess zur produktion von cyclosporin-a und/oder c
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CN1148224C (zh) * 1994-06-01 2004-05-05 株式会社柳韩洋行 含环孢菌素的组合物及其制备方法
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
JP2007056045A (ja) * 1995-05-26 2007-03-08 Nobaruteisu Fuaama Kk サイクロデキストリン組成物
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
TR199901686T2 (xx) * 1997-01-30 1999-09-21 Norvartis Ag Esasen ya�s�z farmakolojik kompozisyonlar� i�eren sert jelatin kaps�ller.
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
ATE314388T1 (de) 1997-10-08 2006-01-15 Isotechnika Inc Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
NZ531946A (en) * 2001-10-19 2005-09-30 Isotechnika Inc Preconcentrate formulations comprising cyclosporin analogue microemulsions that reduce adverse effects while maintaining high bioavailability
JP4261355B2 (ja) 2001-10-19 2009-04-30 アイソテクニカ インコーポレイテッド シクロスポリン類似体の合成法
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DE602004031356D1 (de) 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
US7691812B2 (en) 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
CA2840734A1 (en) * 2011-06-29 2013-01-03 Allergan, Inc. Macrogol 15 hydroxystearate formulations
MX2017015250A (es) * 2015-05-29 2018-04-11 Oculis Ehf Formacion de nanoparticulas de ciclosporina a/ciclodextrina.
CN105997863B (zh) * 2016-07-21 2018-09-04 河南省眼科研究所 环孢素a滴眼液及其制备方法
EP4194011A1 (en) 2016-11-29 2023-06-14 Oculis SA Preparation of cyclodextrin nanoparticle for ophthalmic drug delivery
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
MX2021015767A (es) 2019-07-01 2022-01-27 Oculis SA Metodo para estabilizar el ph de una composicion acuosa que comprende un farmaco.
CN112724200B (zh) * 2019-10-28 2022-09-27 上海云泽生物科技有限公司 一种稳定环孢霉素a的稀释液及其应用
JP2023548966A (ja) 2020-11-09 2023-11-21 スカイ・セラピューティクス・カンパニー・リミテッド 固相のシクロスポリンa及びこれを含む分散組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
BE895724A (fr) * 1982-02-01 1983-07-28 Sandoz Sa Nouvelle utilisation therapeutique de la dihydrocyclosporine d
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
EP0170623B1 (en) * 1984-08-02 1990-11-28 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine

Also Published As

Publication number Publication date
AU1738688A (en) 1988-12-22
JPS6485921A (en) 1989-03-30
ES2033429T3 (es) 1993-03-16
GR3004199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-31
EP0294239B1 (en) 1992-02-19
US5051402A (en) 1991-09-24
AU607506B2 (en) 1991-03-07
DE3868438D1 (de) 1992-03-26
CA1325973C (en) 1994-01-11
EP0294239A1 (en) 1988-12-07
JP2577049B2 (ja) 1997-01-29
HK28097A (en) 1997-03-06

Similar Documents

Publication Publication Date Title
ATE72629T1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
ES2033086T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
DE69011059D1 (de) Heterozyklische Acylaminothiazolderivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen.
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
IT1232243B (it) Composizioni farmaceutiche a base di ciclosporine
MY101593A (en) Sustained release preparation.
ATE203411T1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
DE68915291D1 (de) Verschlusskörpr zur verabreichung einer physiologisch aktiven substanz.
SE9503143D0 (sv) New preparation
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
WO1991015512A3 (en) Hiv envelope polypeptides
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
DE3776620D1 (de) 3-propenylcephemderivate, ihre herstellung, zwischenverbindungen, pharmazeutische praeparate und anwendung.
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
ATE70445T1 (de) Pharmazeutische praeparate.
RU96114157A (ru) Способ лечения острых отравлений
IT1226072B (it) Soluzioni iniettabili pronte all'uso contenenti un glicoside antraciclinico antitumorale.
SE8902458D0 (sv) Laekemedelskomposition
RU96106437A (ru) Способ лечения сухой остаточной полости после перенесенного абсцесса легкого
ES2060057T3 (es) Soluciones acuosas conteniendo proteina.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
ATE111731T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time